/News

The USFDA has reviewed and commented on the results of the phase 1 clinical trial of NBM-BMX and suggested changes on the draft clinical protocol of the phase 2 program

In 2018, in a letter approving the initiation of phase 1 clinical trials, the USFDA requested NatureWise schedule an end of phase 1 (EOP1) meeting with the FDA when NatureWise completed the phase 1 clinical program. In September 2021, NatureWise completed a phase 1 clinical trial in the USA, submitted the trial results to the USFDA along with a draft of the phase 2 study protocol for glioblastoma multiforme, and requested an EOP1 meeting. In December 2021, in the response letter for the EOP1 meeting, the USFDA commented on the trial results and suggested changes for the phase 2 clinical study [...]

2022-01-06T15:29:18+00:00 2022 / 01 / 06|Categories: News|

NBM-BMX RECEIVED US FDA APPROVAL TO PROCEED PHASE I CLINICAL TRIAL

NatureWise’s new chemical entity, NBM-MBX, received US Food and Drug Administration (FDA) approval on July 24th to proceed Phase I clinical trial. NBM-MBX is an isoform-selective histone deacetylase 8 (HDAC 8) inhibitor. The high specificity produces less side effects than those of non-selective HDAC inhibitors. […]

2019-07-15T15:18:47+00:00 2018 / 07 / 26|Categories: News|

NATUREWISE BIOTECH & MEDICALS CORPORATION PARTICIPATED IN BIO INTERNATIONAL CONVENTION 2018 HELD AT BOSTON CONVENTION & EXHIBITION CENTER IN BOSTON

The Biotechnology Innovation Organization (BIO) is holding its 2018 International Convention from June 4 to 7 in Boston, MA, USA. […]

2018-08-23T16:13:39+00:00 2018 / 05 / 22|Categories: News|

NBM ANNOUNCES RECEIVING INVENTION PATENT, TITLED “PRENYLFLAVANONE COMPOUNDS FOR MODULATING DIABETES”, FROM ISRAELI’S PATENT OFFICE

The Israeli’s Patent Office approved the application of “PRENYLFLAVANONE COMPOUNDS FOR MODULATING DIABETES” from NBM for an invention patent with the certificate No. 231754. Prenylflavanone compounds have been used in NBM’s product, SugarBless, for blood sugar control.

2018-05-25T18:39:44+00:00 2018 / 05 / 18|Categories: News|Tags: |

NBM ANNOUNCES RECEIVING THE US INVENTION PATENT FOR “EXTRACT OF TAIWANESE PROPOLIS FOR TREATING OCULAR DISEASES”

The US Patent Invention No. 14/632,894 "EXTRACT OF TAIWANESE PROPOLIS FOR TREATING OCULAR DISEASES" filed by NatureWise was approved by the U.S. Patent and Trademark Office. Frequent usage of 3C products lead to eye damage. Our extract of Taiwanese green propolis has been found to protect the eye.

2018-05-25T18:37:20+00:00 2018 / 01 / 04|Categories: News|Tags: |

NBM-BMX, A SPECIFIC HDAC 8 INHIBITOR, HAS BEEN QUALIFIED TO BE A NEW DRUG BY TAIWAN’S MINISTRY OF ECONOMIC AFFAIRS ALONG WITH THE COMPANY TO HAVE “BIOTECH NEW DRUG COMPANY” STATUS.

“NBM-BMX, a specific histone deacetylase 8 inhibitor, developed solely by NBM from scratch, has met the requirements by the "Biotech New Drug Industry Development Regulations" and other related provisions, to be recognized as an innovative new drug by Industrial Development Bureau, Ministry of Economic Affairs. With the endorsement, the company can get a number of tax-favored benefits.

2018-05-25T18:30:26+00:00 2016 / 10 / 25|Categories: News|

CITY OF HOPE, NATUREWISE ANNOUNCE LICENSE AGREEMENT FOR NEW TARGETED CANCER THERAPY

NatureWise will commercially develop HDAC8 inhibitors patented by City of Hope, collaborators.   City of Hope today announced that it has licensed its HDAC8 inhibitors patent exclusively to NatureWise Biotech & Medicals Corporation, a pharmaceutical company in Taipei, Taiwan.   Read more: https://www.cityofhope.org/news/city-of-hope-naturewise-announce-license-agreement

2018-05-25T18:46:25+00:00 2016 / 09 / 30|Categories: News|Tags: |
error: Content is protected !!